Why Are CME Shares Falling Today?

This evening we watched CME drop -2.5% to a price of $211.76 per share. The large-cap Capital Markets company is now trading -7.3% below its average target price of $228.43. Analysts have set target prices ranging from $180.0 to $250.0 per share for CME, and have given the stock an average rating of buy.

The stock has a very low short interest at 1.0%, and a short ratio of 2.29. The company's insiders own 0.46% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 88.5% of CME's shares being owned by this investor type.

Institutions Invested in CME

Date Reported Holder Percentage Shares Value
2023-06-30 Vanguard Group Inc 9% 33,309,592 $7,053,639,018
2023-09-30 Blackrock Inc. 6% 23,241,387 $4,921,595,983
2023-06-30 JP Morgan Chase & Company 4% 15,984,554 $3,384,889,067
2023-06-30 State Street Corporation 4% 15,950,459 $3,377,669,110
2023-06-30 Capital International Investors 4% 13,996,964 $2,963,997,019
2023-06-30 Capital World Investors 4% 13,192,611 $2,793,667,232
2023-09-30 Capital Research Global Investors 2% 9,004,219 $1,906,733,365
2023-09-30 Geode Capital Management, LLC 2% 7,391,000 $1,565,118,119
2023-09-30 Bank Of New York Mellon Corporation 2% 7,091,141 $1,501,619,979
2023-09-30 Parnassus Investments, LLC 2% 5,643,801 $1,195,131,268

Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on CME.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.